TAmiRNA GmbH

📢 Uncovering the potential of tRNAs as biomarkers in ESKD! We're excited to share the latest research of our collaborators, published in Thrombosis and Haemostasis, exploring the potential of tRNAs as biomarkers for thromboembolism and bleeding in end-stage kidney disease (ESKD) patients. The study aimed to identify small noncoding RNAs (sncRNAs) as novel biomarkers to predict thromboembolism and bleeding in patients with end-stage kidney disease (ESKD)—a population with a high risk for these complications. 🔍 Key Findings: - No significant differential expression of miRNAs was observed for either ischemic stroke or major bleeding. - Notably, four tRNAs were significantly differentially expressed in ischemic stroke cases, and seven in major bleeding cases (FDR<0.1), using our dedicated tRNA analysis workflow. 🔬 Conclusions and Implications: While miRNAs did not show differential expression, our findings underscore tRNAs as promising biomarkers for thromboembolic and bleeding risks in ESKD. This study paves the way for further research to refine the detection and prevention of life-threatening complications in ESKD patients. Stay tuned as we continue exploring innovative approaches to better understand and manage risks in high-need patient groups. Read the full study: https://lnkd.in/eVey7Y5h #Biomarker #ESKD #RNAseq #Thromboembolism #Hemodialysis #PrecisionMedicine #tRNAs

Great to connect with so many brilliant minds at the EV Forum last week! Thanks to the organizers Precision Medicine Forum for a fantastic event.

Don't miss out on our webinar together with Biomedica Immunoassays!

🌟 Advancing EV Characterization and Therapeutics at the Precision EV Forum! 🌟 Excited to share that TAmiRNA GmbH and Evercyte GmbH will join forces at the upcoming Precision EV Forum in Cambridge! 🚀 As key members of the EVscale® consortium, they’ll be showcasing cutting-edge solutions in EV (#extracellularvesicles) characterization and production. - Evercyte GmbH's Clinical-Grade EVs: Harnessing the potential of telomerized MSC-derived EVs for therapeutic applications. - Phoenestra GmbH's Bioreactor Technology: Enabling faster, scalable EV production. - TAmiRNA GmbH's Advanced Multiomic Capabilities: Unlocking the power of RNA cargo analysis for biomarker discovery and therapeutics development. Catch us at Cripps Court Conference Centre! 💡🔬 #PrecisionMedicine #EVscale #Biomarkers #Therapeutics #Biotech #Innovation #TAmiRNA #Evercyte #EVForum

🌟 New Publication Alert! 🌟 Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated #miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of miRNAs such as mmu-miR-466i-5p and mmu-miR-1195 in both serum and bone marrow of diabetic mice. Dysregulated miRNAs were linked to pathways associated with diabetes-related signaling and diabetic bone disease, shedding light on potential mechanistic pathways. Cell-type enrichment analysis pointed towards miRNAs enriched in specific cell types like immune cells, hepatocytes, and mesenchymal stem cells, which could hold the key to understanding T2DM-induced bone fragility. This study emphasizes the power of miRNAs as #biomarkers for diseases like T2DM, offering new perspectives on diabetic bone disease. 🔗 Read the full study [https://lnkd.in/gvwdezUe]. #Type2Diabetes #BoneFragility #miRNA #Genomics #ComputationalBiology #Biomarkers #T2DM #ScientificResearch #DiabeticBoneDisease #Biology #PrecisionMedicine #BoneHealth

🎉 Celebrating the Nobel Prize in Physiology or Medicine 2024! 🎉 Congratulations to Victor Ambros and Gary Ruvkun, this year’s Nobel Laureates, for their pioneering discovery of microRNAs—tiny but powerful molecules that regulate gene expression and have reshaped our understanding of biology, aging, cancer, and development. At TAmiRNA GmbH, we’ve been deeply inspired by this breakthrough and have dedicated over 10 years to harnessing the potential of microRNAs. We’ve developed cutting-edge diagnostic tools that leverage microRNAs as biomarkers, with our regulatory approved hepatomiR® device leading the way in improving liver cancer patient care across Europe. Our passion for innovation has resulted in over 100 scientific publications, and we’re proud to contribute to advancing this transformative field. The Nobel Prize serves as a reminder of the impact that these discoveries can have on medical technologies, and we’re committed to pushing the boundaries further—developing novel diagnostic and therapeutic solutions based on this incredible science. 🔬 Let’s continue to drive innovation in healthcare together! #NobelPrize #microRNA #Innovation #TAmiRNA #MedicalTechnology #Biotech #CancerResearch #LiverCancer #Diagnostics

🌟 Exciting News from TAmiRNA GmbH at the GSEV 2024 Scientific Conference! We are thrilled to announce that TAmiRNA will contribute a poster at the upcoming German Society for Extracellular Vesicles (GSEV) Autumn Meeting 2024, presenting our recent advancements in the biodistribution of extracellular vesicles (EVs). The poster will be presented by our expert, Magdalena Mecking. 💡 Highlighting Our Cutting-Edge EV Characterization Services 💡 TAmiRNA will also use the conference’s networking sessions to introduce our unique EV characterization services. These services are designed for academic and industry researchers exploring the use of EVs as biomarkers or therapies. With a special focus on transcriptomic analysis of small and large RNAs, powered by our NextGen sequencing miND® platform, we offer advanced multiomics capabilities to help accelerate discoveries. 🔗 Learn more about our innovative work at www.tamirna.com. https://lnkd.in/df4YViUJ   #ExtracellularVesicles #EVResearch #Transcriptomics #miRNA #Biomarkers #GSEV2024 #NextGenSequencing #TAmiRNA #InnovationInBiotech

🚀 Exciting news! A new study from the Università degli Studi di Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. 🔬 This research, leveraging TAmiRNA GmbH's Next-Generation Sequencing (NGS)-based #miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. 💡 This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific #EVs and their miRNA cargo. Read the full study: https://lnkd.in/d2QKBTND #miRNA #EVs #TAmiRNA #biomarkers #NGS #ClinicalPharmacology #TranslationalScience #PediatricMedicine

🚀 Exciting News from #EVscale™! 🚀 We are thrilled to announce that #EVscale™, a groundbreaking collaboration between TAmiRNA GmbH, Evercyte GmbH, and Phoenestra GmbH, will be showcased at the upcoming event at the University Clinic of Dentistry, Medical University Vienna, 16.-17. September 2024. Our expert team, including Dr. Matthias Hackl (TAmiRNA, CEO), Dr. Regina Grillari (Evercyte, CSO), and Dr. Klaus Graumann (Phoenestra, CEO), will be there to present the latest advancements in scaling the manufacture of extracellular vesicles (EVs). 🔬 The #EVscale™ platform technology brings together: Evercyte GmbH’s ‘cell factory’ expertise, creating telomerized MSCs from various tissues TAmiRNA GmbH’s cutting-edge capabilities in extended RNA and protein characterization for EV composition and biological functions Phoenestra GmbH’s proprietary platform for scalable EV production and enrichment. Join us in learning more about how #EVscale™ is shaping the future of EV production and bringing us closer to scalable, commercial manufacturing solutions! #EVscale™ #EVs #Biotech #Innovation #RegenerativeMedicine #CellTherapy #ScalingUp #TAmiRNA #Evercyte #Phoenestra

TAmiRNA at EUROTOX 2024 in Copenhagen! We're excited to be presenters at EUROTOX 2024, showcasing our latest innovations in toxicology. 🎤 Presentation Alert: On September 10, our CEO & CSO, Dr. Matthias Hackl, will discuss “Small RNA-sequencing based discovery of microRNAs for CNS-injury biomarkers” during the EUROTOX Short Orals Session. He’ll highlight the efforts of TAmiRNA and the IMI consortium TransBioLine in advancing microRNAs as biomarkers of drug-induced brain injury. 📊 Poster Presentation: TAmiRNA will also bring a poster (P06-01) to the conference, authored by Senior Scientist, Kseniya Khamina-Kotisch, PhD, on “NGS-based discovery of microRNA biomarkers of drug-induced pancreatic injury (DIPI),” showcasing the merits of small RNA-sequencing (miND) for biomarker discovery. Looking forward to insightful discussions at EUROTOX! #EUROTOX2024 #Toxicology #Multiomics #RNAseq #TAmiRNA #miND #microRNA #NGS #TransBioLine #drugsafety